Norway CRo. Cancer in Norway 2019 - Cancer incidence, mortality, survival and prevalence in Norway. 2020
Wild CPWE, Stewart BW, editors. World Cancer report: Cancer research for Cancer prevention. Lyon, France: International Agency for Research on Cancer; 2020.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.
Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;131(1):159–67.
Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, et al. Association between common risk factors and molecular subtypes in breast cancer patients. Breast. 2013;22(3):344–50.
Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat. 2014;144(1):1–10.
Valla M, Vatten LJ, Engstrom MJ, Haugen OA, Akslen LA, Bjorngaard JH, et al. Molecular subtypes of breast Cancer: long-term incidence trends and prognostic differences. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016;25(12):1625–34.
Engstrøm MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA, et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat. 2013;140(3):463–73.
Waks AG, Winer EP. Breast Cancer treatment: a review. Jama. 2019;321(3):288–300.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer Nature Reviews Disease Primers. 2019;5(1):66.
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50.
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367–74.
Aromaa-Häyhä A, Auvinen P, Sarkeala T, Heinävaara S, Lamminmäki A, Malila N, et al. Improved diagnostics and change of tumour characteristics in breast cancer: a retrospective study over two decades. Acta Oncol. 2018;57(10):1331–8.
Mesa-Eguiagaray I, Wild SH, Rosenberg PS, Bird SM, Brewster DH, Hall PS, et al. Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. Br J Cancer. 2020;123(5):852–9.
Mullooly M, Murphy J, Gierach GL, Walsh PM, Deady S, Barron TI, et al. Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004–2013): amassing data from independent Western populations provide etiologic clues. Eur J Cancer. 2017;86:326–33.
Anderson WF, Katki HA, Rosenberg PS. Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst. 2011;103(18):1397–402.
Anderson WF, Rosenberg PS, Petito L, Katki HA, Ejlertsen B, Ewertz M, et al. Divergent estrogen receptor-positive and-negative breast cancer trends and etiologic heterogeneity in Denmark. Int J Cancer. 2013;133(9):2201–6.
Acheampong T, Kehm RD, Terry MB, Argov EL, Tehranifar P. Incidence trends of breast Cancer molecular subtypes by age and race/ethnicity in the US from 2010 to 2016. JAMA Netw Open. 2020;3(8):e2013226.
Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007;99(15):1152–61.
Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S. Breast cancer incidence trends in Norway--explained by hormone therapy or mammographic screening? Int J Cancer. 2012;130(12):2930–8.
Weedon-Fekjær H, Bakken K, Vatten LJ, Tretli S. Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. BMJ (Clinical research ed). 2012;344:e299.
Hanahan D. Weinberg RAJc. The hallmarks of cancer. 2000;100(1):57–70.
Hanahan D, RAJc W. Hallmarks of cancer: the next generation. cell. 2011;144(5):646–74.
Hanahan D. Hallmarks of Cancer: new dimensions. Cancer Discovery. 2022;12(1):31–46.
van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004;57(7):675–81.
de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer. 2007;96(10):1504–13.
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65.
Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen international consensus guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541–57.
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(8):1160–7.
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7(1):96.
Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med brystkreft: Helsedirektoratet; 2022.
Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast (Edinburgh, Scotland). 2008;17(4):323–34.
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in breast Cancer: updated recommendations from the international Ki67 in breast Cancer working group. JNCI: Journal of the National Cancer Institute. 2021;113(7):808–19.
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2015;26(8):1533–46.
FDA approves abemaciclib with endocrine therapy for early breast cancer fda.gov: U.S Food & Drug Administration; 2021 Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-endocrine-therapy-early-breast-cancer.
Sandvei MS, Opdahl S, Valla M, Lagiou P, Vesterfjell EV, Rise TV, et al. The association of women's birth size with risk of molecular breast cancer subtypes: a cohort study. BMC Cancer. 2021;21(1):299.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–10.
Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181–5.
Kvåle G, Heuch I, Eide GE. A prospective study of reproductive factors and breast cancer. I Parity Am J Epidemiol. 1987;126(5):831–41.
Holmen J, Midthjell K, Krüger Ø, Langhammer A, Holmen TL, Bratberg GH, et al. The Nord-Trøndelag health study 1995-97 (HUNT 2). Norsk Epidemiologi. 2011;13(1):19–32.
Sandvei MS, Lagiou P, Romundstad PR, Trichopoulos D, Vatten LJ. Size at birth and risk of breast cancer: update from a prospective population-based study. Eur J Epidemiol. 2015;30(6):485–92.
Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ (Clinical research ed). 2009;338:b2393.
Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol. 2006;59(10):1087–91.
Research-based evaluation of the Norwegian Cancer Screening Program Regjeringen. Oslo: The Research Council of Norway; 2015. Available from: https://www.regjeringen.no/contentassets/444d08daf15e48aca5321f2cefaac511/mammografirapport-til-web.pdf.
Crispo A, Barba M, D'Aiuto G, De Laurentiis M, Grimaldi M, Rinaldo M, et al. Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series. BMC Cancer. 2013;13:15.
Sihto H, Lundin J, Lehtimäki T, Sarlomo-Rikala M, Bützow R, Holli K, et al. Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res. 2008;14(13):4103–10.
Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast Cancer (monarchE). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020;38(34):3987–98.
Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Annals of oncology : official journal of the European Society for Medical Oncology. 2021;32(12):1571–81.
Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med brystkreft, 2019. Helsedirektoratet.
Focke CM, van Diest PJ, Decker T. St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods. Breast Cancer Res Treat. 2016;159(2):257–63.
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Annals of oncology : official journal of the European Society for Medical Oncology. 2009;20(8):1319–29.
Group NBC. Oversikt NBCGs retningslinjer for adjuvant systemisk behandling. https://nbcg.no/: Norwegian breast cancer group; 2015.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. "Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer” 2011. Annals of oncology 2011;22(8):1736–1747.
Knutsvik G, Stefansson IM, Aziz S, Arnes J, Eide J, Collett K, et al. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLoS One. 2014;9(11):e112121.
Grillo F, Bruzzone M, Pigozzi S, Prosapio S, Migliora P, Fiocca R, et al. Immunohistochemistry on old archival paraffin blocks: is there an expiry date? J Clin Pathol. 2017;70(11):988.
Combs SE, Han G, Mani N, Beruti S, Nerenberg M, Rimm DL. Loss of antigenicity with tissue age in breast cancer. Lab Investig. 2016;96(3):264–9.
Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 2006;8(6):216.
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Journal of immunology. 1984;133(4):1710–5.
Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology. 2006;48(6):674–82.
Batistatou A, Televantou D, Bobos M, Eleftheraki AG, Kouvaras E, Chrisafi S, et al. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays. Anticancer Res. 2013;33(5):2139–45.
Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochimica et Biophysica Acta (BBA) reviews on. Cancer. 2015;1856(1):73–85.
Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program. Breast Cancer Res. 2017;19(1):10.
Danaei G, Vander Hoorn S, Lopez AD, Murray CJL, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005;366(9499):1784–93.